Clinical features and death risk factors of pneumocystis jirovecii pneumonia in kidney disease patients with immunosuppressive therapy
10.3760/cma.j.cn112150-20230823-00116
- VernacularTitle:免疫抑制治疗的肾脏疾病患者并发肺孢子菌肺炎的临床特点及死亡风险因素分析
- Author:
Cun SHEN
1
;
Rong XU
Author Information
1. 首都医科大学附属北京中医医院肾病科，北京 100010
- Keywords:
Pneumocystis jirovecii pneumonia;
Kidney disease;
Immunosuppressive therapy;
Clinical characteristics;
Death risk factors
- From:
Chinese Journal of Preventive Medicine
2024;58(5):673-678
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the clinical features and death risk factors of pneumocystis jirovecii pneumonia (PJP) in kidney disease patients with immunosuppressive patients. A Retrospective case series study was performed in 52 PJP patients with kidney disease who received immunosuppressive therapy in Nephrology or Respiratory department of Peking University First Hospital from January 1, 2006 to August 31, 2021. Patients were divided into survival group (36 cases) and death group (16 cases) according to their clinical outcomes. Univariate analysis was performed to compare the differences of clinical features between the two groups. Multivariate logistic regression model was used to analyze the death risk factors. The results showed that the median serum creatinine was 192.5 (109.8, 293.7) μmol/L, and the incidence of acute kidney injury was 63.5% (33/52). Univariate analysis showed that age ( t=1.197, P=0.030), C-reactive protein level ( t=2.378, P=0.022), time from onset to diagnosis ( χ 2=6.62, P=0.010), PJP severity ( χ 2=5.482, P=0.019), complicated with septic shock ( χ 2=3.997, P=0.046), mechanical ventilation ( χ 2=11.755, P=0.001), and blood purification therapy ( χ 2=4.748, P=0.029) were statistically significant. There were no statistically significant differences between the two groups in gender, duration and dosage of hormone therapy before PJP onset, intravenous methylprednisolone pulse therapy, immunosuppressant use, and serum creatinine level before and after hospitalization for anti-PJP treatment (all P>0.05). Multivariate analysis showed that the time from onset to diagnosis of PJP was >10 days ( OR=40.945, 95% CI: 1.738-451.214; P=0.021) and severe PJP ( OR=25.502, 95% CI: 1.426-74.806; P=0.028) was an independent death risk factor for kidney disease complicated with PJP of immunosuppressive therapy. In conclusion, the time from onset to diagnosis of PJP and PJP severity are independent death risk factors in patients with kidney disease complicated with PJP of immunosuppressive therapy. Close attention should be paid to oxygenation condition and early diagnosis can prevent the aggravation of PJP and improve the prognosis.
